National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 20507 [2020-07709]
Download as PDF
<![CDATA[
20507
Federal Register / Vol. 85, No. 71 / Monday, April 13, 2020 / Notices
number of older adults have access to a
higher quality of life. Therefore, in
addition to the legislative mandate
under the OAA, it is important for
program integrity and function to
evaluate the LTCOP.
To comment and review the proposed
data collection please visit the ACL
effectively report its results to the
President, to Congress, to the
Department of Health and Human
Services and to the public.
The information will also aid in
program refinement and continuous
improvement. The more productive
ACL/AoA’s programs, the greater the
Respondent/data
collection activity
Estimated Program Burden
ACL estimates the burden associated
with this collection of information as
follows:
Responses
per
respondent
Hours per
response
Annual
burden hours
Focus Group—Facility staff including participant information .........................
Focus Group—Residents/family including participant information ..................
Interview—Stakeholders ..................................................................................
Survey—Facility Administrator .........................................................................
Survey—Former Ombudsmen .........................................................................
Survey—SUA director ......................................................................................
16
24
40
1840
12
53
1
1
1
1
1
1
0.33
1
1
0.33
1
0.5
5.3
24
40
607.2
12
26.5
Total: .........................................................................................................
1985
........................
4.16
715
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3E71 Bethesda, MD 20892–9834, 301–761–
7749, lee.klinkenberg@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 6, 2020.
Mary Lazare,
Principal Deputy Administrator.
[FR Doc. 2020–07668 Filed 4–10–20; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
respondents
website at https://www.acl.gov/aboutacl/public-input.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Statistical and Data
Coordinating Center (SDCC) for Clinical
Research in Infectious Diseases.
Date: May 11, 2020.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E71,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Lee G. Klinkenberg, Ph.D.,
Scientific Review Program, Division of
VerDate Sep<11>2014
17:57 Apr 10, 2020
Jkt 250001
Dated: April 7, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–07709 Filed 4–10–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Prospective Grant of an Exclusive
Patent License: Interinstitutional
Agreement—Institution Lead:
Graphene Oxide-Polycarbonate TrackEtched Nanosieve Platform for
Sensitive Detection of Human
Immunodeficiency Virus Envelope
Glycoprotein
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Indian Patent Applications listed in the
Supplementary Information section of
this notice to Chaudhary Charan Singh
Haryana Agricultural University
(CCSHAU) located in Hisar, India.
SUMMARY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Jasmine J. Yang, Ph.D.,
(Senior) Licensing and Patenting
Manager, NCI Technology Transfer
Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892–
9702 (for business mail), Rockville, MD
20850–9702 Telephone: (240)-276–5530;
Facsimile: (240)-276–5504 Email:
jasmine.yang@nih.gov.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
National Institutes of Health
AGENCY:
Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before April 28, 2020 will be
considered.
DATES:
Intellectual Property
Indian Patent Application Serial No.
201711002764, filed February 24, 2017
entitled ‘‘Graphene oxide-polycarbonate
track-etched nanosieve platform for
sensitive detection of human
immunodeficiency virus envelope
glycoprotein.’’
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the CCS Haryana
Agricultural University and Government
of the United States of America as
represented by the Secretary,
Department of Health & Human
Services.
The prospective patent license will be
for the purpose of consolidating the
patent rights to CCSHAU, the co-owners
of said rights, for commercial
development and marketing.
Consolidation of these co-owned rights
is intended to expedite development of
the invention, consistent with the goals
E:\FR\FM\13APN1.SGM
13APN1
]]>Agencies
[Federal Register Volume 85, Number 71 (Monday, April 13, 2020)]
[Notices]
[Page 20507]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-07709]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Statistical and Data Coordinating
Center (SDCC) for Clinical Research in Infectious Diseases.
Date: May 11, 2020.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3E71,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Lee G. Klinkenberg, Ph.D., Scientific Review
Program, Division of Extramural Activities, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3E71 Bethesda, MD 20892-9834, 301-761-7749,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: April 7, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-07709 Filed 4-10-20; 8:45 am]
BILLING CODE 4140-01-P
